GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » Valuation Rank

Kaleido Biosciences (Kaleido Biosciences) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is Kaleido Biosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Kaleido Biosciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of Kaleido Biosciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaleido Biosciences (Kaleido Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » Valuation Rank
Comparable Companies
NPTX GSTC BZYR CAPS PCNT QBIO USRM ISCO ENDV NTRR OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Lexington, MA, USA, 02421
Website
http://www.kaleido.com
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.
Executives
Alison S Long officer: Chief Medical Officer KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Van Hylckama Vlieg Johan officer: Chief Scientific Officer C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Daniel L Menichella director, officer: Chief Executive Officer 79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709
Kyriazi Theo Melas director 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Nutritional Health Ltp Fund General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Anne Prener director C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
William E. Duke officer: CHIEF FINANCIAL OFFICER C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Richard William Scalzo officer: Principal Accounting Officer 25 ALBERTA LANE, HOLLISTON MA 01746
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Jerald Korn officer: General Counsel 128 GORDON RD, NEWTON MA 02468
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Michael W Bonney director, officer: Executive Chair 65 HAYDEN AVE, LEXINGTON MA 02421
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142